Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

NCT02585401 ·Status: COMPLETED

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

NCT00964795 ·Status: COMPLETED ·Phase: PHASE3

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

NCT02581891 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)

NCT02818998 ·Status: COMPLETED ·Phase: PHASE3

A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).

NCT04641234 ·Status: COMPLETED

A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America

NCT03470103 ·Status: COMPLETED

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01521559 ·Status: COMPLETED ·Phase: PHASE3

Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece

NCT02821247 ·Status: COMPLETED

Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.

NCT01918878 ·Status: UNKNOWN ·Phase: PHASE4

Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

NCT02541084 ·Status: COMPLETED

Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

NCT02279537 ·Status: COMPLETED

Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU Brugmann

NCT04891835 ·Status: COMPLETED

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)

NCT00637377 ·Status: COMPLETED ·Phase: PHASE3

Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept

NCT02125864 ·Status: COMPLETED ·Phase: PHASE4

An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies

NCT03521895 ·Status: COMPLETED

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

NCT02615496 ·Status: COMPLETED

Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)

NCT02142296 ·Status: COMPLETED ·Phase: PHASE4

A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

NCT06591598 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

NCT02540954 ·Status: COMPLETED ·Phase: PHASE3

Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients

NCT03382587 ·Status: COMPLETED

Use of Eylea for the Treatment of an Optic Nerve Hemangioma

NCT01714115 ·Status: NO_LONGER_AVAILABLE

Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration

NCT01914380 ·Status: COMPLETED

Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.

NCT03714308 ·Status: COMPLETED

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

NCT04126317 ·Status: COMPLETED ·Phase: PHASE2

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

NCT05473715 ·Status: TERMINATED ·Phase: PHASE4